New eye lens could let cataract patients ditch glasses
NCT ID NCT07607860
First seen Jun 25, 2026 · Last updated Aug 07, 2026 · Updated 4 times
Summary
This study tests a new type of artificial lens for cataract surgery that may adjust focus like a natural lens. About 100 adults needing cataract surgery will get this lens in one eye and a standard lens in the other. Researchers will check for complications and measure vision improvement over three years.
What this could mean
Our plain-language read of the trial. This is informational only, not medical advice or a prediction.
- Active substance
- accommodating intraocular lens (device)
- What this could lead to
- If successful, this lens could help cataract patients see clearly at multiple distances without glasses.
- What could go wrong
- This is an early feasibility study with only 100 participants. The lens may not improve vision as hoped, and there are risks like swelling or lens dislocation.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Study facts
What this study's own registry entry says, in plain language.
- Phase
-
Not a phased trial
Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.
- Participants
-
About 100 people
The number the study aims to enrol. It can still change while the study runs.
- Expected to start
-
Sep 2026
An estimate. Start dates often move.
- Expected to finish
-
Dec 2030
An estimate. End dates often move.
- Lead sponsor
-
A company
The lead sponsor is a pharmaceutical, biotech, or medical-device company.
Who can take part
This study's own entry requirements. Only the study team can say for certain whether you qualify.
- Ages
-
21 years and older
- Sex
-
Anyone
- Healthy volunteers
-
Not accepted
This study is not open to healthy volunteers. The entry requirements below say who it is open to.
Show the full entry requirements Hide the full entry requirements
Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.
Inclusion Criteria: * Adults who are at least 21 years of age or older. * Scheduled to undergo primary intraocular lens implantation for the correction of aphakia following phacoemulsification extraction of a senile cataract. * Clear intraocular media other than cataract. * Potential visual acuity of 20/32 or better in both eyes after cataract removal and IOL implantation as determined by diagnostic testing or investigator's judgement. * Preoperative corrected distance visual acuity (CDVA) worse than 20/40 either with or without a glare source present (e.g., Brightness Acuity Tester) or scheduled for cataract removal due to significant cataract-related symptoms/complaints. * Less than or equal to 1.0 diopter (D) of preoperative keratometric astigmatism. * In good general health at screening as determined by the investigator. * Signed written informed consent. * Availability, willingness, and sufficient cognitive awareness to comply with examination procedures and schedule. Exclusion Criteria: * Planned secondary procedures (such as LASIK) during the term of the study; Nd YAG capsulotomy is permitted. * Taking systemic medications that may confound the outcome or increase the risk to the subject. * Ocular conditions that may predispose for future complications. * Previous intraocular or corneal surgery that might confound the outcome of the investigation or increase the risk to the subject. * Pregnant, lactating during the course of the investigation, or with another condition associated with fluctuation of hormones that could lead to refractive changes. * Diagnosed degenerative visual disorders (e.g. macular degeneration or other retinal disorders) that are predicted to cause future CDVA loss worse than 20/40. * Any anterior segment pathology (anterior segment or corneal abnormalities, chronic uveitis, iritis, corneal dystrophy, pseudoexfoliation, etc.). * Glaucoma, glaucoma suspect or ocular hypertension, i.e., IOP \> 22 mmHg. * Previous retinal detachment or retinal pathology, including age-related macular degeneration. * Diabetes, currently being treated systemically and with retinopathy. * Systemic or ocular disease that may prevent the patient from achieving CDVA of 20/32 or better post operatively. * Require chronic administration of any topical ophthalmic or systemic medication that may affect accommodation such as mydriatic, cycloplegic and myotic agents; tricyclic antidepressants, phenothiazines, benzodiazepines, first generation antihistamines, anticholinergic agents. * CDVA of 20/32 or worse in the fellow eye not attributable to cataract. * Current participation in, or have participated in, an investigational study, other than this study, within the previous 60 days before the operative day. * Previous ocular surgery in the operative eye, including refractive surgery.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for Aphakia are added.
Genom att skicka in godkänner du våra Användarvillkor
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
How to take part
Only the study team decides who joins. These are the ways to reach them.
-
The official record
ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.
-
A doctor treating you
A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Can newer cataract lenses keep vision clear for years?
- Can ultrasound reveal hidden lens misalignment after cataract surgery?
- New lens aims to sharpen vision after cataract surgery
- Which eye drop works best after cataract surgery? new study aims to find out
- New lens implant shows promise for cataract patients
- New lens implant aims to sharpen sight after cataracts